Gilead Sciences' Hepatitis Drug in Spotlight at Major Medical Meeting
It’s just about showtime for Gilead Sciences (GILD) and its experimental hepatitis C drug. When specialist doctors from around the world gather in Spain next week to learn about new drugs in development for liver diseases data for Gilead’s GS-7977 will be closely scrutinized and among the most anticipated research presented. The company hopes to show it has a real potential winner of a drug to treat the liver-wasting virus hepatitis C. The big medical meeting the International Liver Conference begins Wednesday and some scientific abstracts have been released in advance of the five-day gathering. However a pair of ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here